DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Dr. Reddy's Laboratories Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 53 min ago·7 Oct 2026, 9:04 am

DR. Reddy S Laboratories

Dr. Reddy's Laboratories has informed stock exchanges that it has issued a certificate under the SEBI (Depositories and Participants) Regulations, 2018. This regulatory filing is a standard administrative step that the company undertakes to comply with securities market rules. The certificate confirms the company's adherence to the legal framework governing its shareholding and depository operations.

For investors, this news is largely procedural and does not indicate any operational or financial changes. It serves as a formal confirmation of compliance, which is a routine requirement for listed entities. The stock's performance is therefore unlikely to be impacted by this specific disclosure.

Investors should monitor the company's upcoming quarterly earnings and clinical trial results for more significant market-moving information. This regulatory update is a routine corporate disclosure and does not alter the company's fundamental business outlook.